GBA's "2021 Stock Phantasma"

Hello from the country. It is very cold. Rainy. House phone is down as usual.

Check this out--

Paymentus stock rallies to post-IPO high as fintech firm gains 45%+ in just three sessions
May 28, 2021 6:30 PM ETPaymentus Holdings, Inc. (PAY)Paymentus Holdings, Inc. (PAY)
  • Paymentus Holdings Inc. (NYSE:PAY) rallied for the second session in three days Friday, taking the fintech’s stock up more than 45% from its IPO price in less than a week.
  • PAY rose to a record $31.81 intraday high Friday before pulling back some to close at a post-IPO high of $30.50, up 8.9% on the day and 45.2% above its $21-a-share initial public offering price. Paymentus had already soared 36.2% in its first post-IPO session Wednesday before giving some of the gains back Thursday.
  • PAY’s platform helps landlords, utilities, auto-loan providers and other businesses electronically bill customers and accept instant payments. Its system is tied in with popular payments platforms like Amazon Pay and PayPal. Consumers can also pay bills with cash or plastic at more than 4,000 Walmart locations.
Wow-- there is another Fintech IPO coming... starts with a K Klaron? Klarian? I'll find it.
I briefly mentioned it here once...

I think the HF asked me if I wanted any " Paymentus " and I had no idea what that was--
I need to stay up to date. My default answer is Yes fortunately...

This could also rub off on my under water play: Buy Now pay later.../// That could run next week... Forgetting the symbol at the moment...
 
DEEP DIVE TIME>


We are also leveraging our technology to access new markets through business development partnerships. The truly incredible thing about our platform-based technology is its broad applicability into new markets. As we approach new attractive cell-based markets, we look for the biggest problems that our customers are having and engage in business development deals with those partners to develop a solution to the problem. We jointly develop workflows, become the solution of record and commercialize those workflows in the broader market. We have done this in cell line development with Amgen where Beacon has become Amgen’s standard platform for cell line development. We are doing it with Ginkgo in synthetic biology.

And our last earnings call, we announced a $17 million deal with a global leader in gene therapy space to adapt the Berkeley Lights platform to enable the selection and manufacturing of stable viral vector producer cell lines. Viral vector producer cell lines are used across multiple therapeutic modalities such as gene therapy, cell therapy, and really any therapy using viral transfection. Today, these therapies rely on costly and difficult to scale transient re-expression cell lines. This is because quickly generating stable producer lines has not been proven possible with current purchase.

We believe that Berkeley Lights technology will make it possible for the first time to execute multi-parameter functional tests, including viral capsid and genomic titers without losing the live biology. Once developed, this will allow us to select stable clones in one to two weeks that will be used to create stable master cell banks, similar to what is being done in cell line development for antibody manufacturing. We believe this will become the new standard for viral vector manufacturing. As it significantly reduces costs, enhances manufacturing predictability, and provides a superior approach from the regulatory perspective. This partnership has progressed into the next phase and we expect these types of partnerships to have a meaningful impact on our growth trajectory over the coming years.

FOCUS STOCK-> I found this my surfing --> It is a supplier to Mrna Bio's (on the upswing) as well as lots of other interesting firms like Amgen!
 
Thanks, stoney. Revenue for the three months ended March 31, 2021 increased 35% year-over-year to $18.6 million with $13.5 million coming from product revenue and $5.1 million from service revenue. Looking at our three revenue streams, direct platform sales totaled $11.1 million in the first quarter of 2021, increasing 18% over the prior year period.

Revenue from joint development agreements and partnerships was $3.1 million in the first quarter of 2021, compared to $1.9 million in the first quarter of 2020. Recurring revenue was $4.4 million in the first quarter of 2021, up 77% over the same period in 2020. The increase as a result of our growing installed base compared to the prior year period. Regionally, the strength in APAC continued into the first quarter and accounted for 45% of our first quarter revenue followed by North America at 40%.

During the quarter, we added 10 platforms to our install base ending with eight total – 85 total placements. As Eric mentioned, eight of these platforms were direct sales and two were placed in connection with the completion of a milestone program where title of the tool passed to the customer.

Gross profit for the first quarter of 2021 was $12.5 million, compared to $10 million in the prior year. Gross margin for the first quarter of 2021 was 67%, compared to 72% :thumbsdown:in the first quarter of 2020. The decline was largely driven by the cumulative impact of the two Ginkgo workflow buy downs during 2020. By executing our buy down rights on the Ginkgo workflows, we gained full commercial rights to the workflows in all target markets, :thumbsup:which allows us to expedite the commercialization of these workflows and leverage them into new partnerships and accelerate growth. Excluding the Ginkgo impact, gross margins for Q1 was approximately 72%. We continue to expect our long-term target for gross margins to be approximately 70%.

Total operating expenses for the first quarter of 2021 were $27.6 million inclusive of $4.5 million of stock-based compensation, compared to $18.2 million in the first quarter of 2020. The increase of $9.4 million was driven by $3.3 million of stock-based compensation, $4.1 million of G&A as we transitioned to a public company, $1.5 million of research and development and a $0.5 million of sales and marketing.

Net loss for Q1 was $15.4 million, :thumbsdown:compared to a loss of $8.4 million in the first quarter of 2020. All net loss numbers are inclusive of stock-based compensation. We ended the quarter with a strong balance sheet consisting of $230 million of cash and cash equivalent.

Turning to our outlook for 2021. We continue to expect revenue to be in the range of $90 million to $100 million representing growth between 40% and 56% over the prior year. As we mentioned in our year end earnings call, we expect revenues to be more heavily weighted to the back half of the year as more business development collaborations and partnerships come online, and as a result of the seasonality we typically experienced in the fourth quarter.

As Eric mentioned, we're rolling out a campaign based subscription offering. This offering will recognize revenue over the subscription term compared to the upfront recognition of a typical equipment sale. As we ramp this offering, it is possible that some previously anticipated CapEx sales may transition to a subscription offering. This could impact quarterly revenues in the near term, but in turn would provide upside to recurring and overall revenues in future periods. The potential variability between CapEx sales and subscription mix is incorporated in our revenue guidance for 2021. And we anticipate placing at least 45 platforms during the year. We do not expect any impact to our long-term gross margin expectation of 70% from the new subscription model.

<< Always tricky when you merge into subscription but here it is only a partial merge >>
 
Alger Small Cap on Berkeley Lights (BLI): “We Believe the Base Business Remains Strong”

April 19, 2021

Alger, an investment management firm, published its “Alger Small Cap Focus Fund” first quarter 2021 investor letter – During the quarter, the largest portfolio sector weightings were Health Care and Information Technology. The largest sector overweight was Health Care. Class A shares of the Alger Small Cap Focus Fund underperformed the Russell 2000 Growth Index during the first quarter of 2021.

Alger Small Cap Focus Fund, in their Q1 2021 investor letter, mentioned Berkeley Lights, Inc. (NASDAQ: BLI) and shared their insights on the company. Berkeley Lights, Inc. is an Emeryville, California-based digital cell biology company that currently has a $3.2 billion market capitalization. Since the beginning of the year, BLI delivered a -46.39% return, while its 3-month gains are also down by -42.77%. As of April 16, 2021, the stock closed at $47.93 per share.

Here is what Alger Small Cap Focus Fund has to say about Berkeley Lights, Inc. in their Q1 2021 investor letter:

"Berkeley Lights Inc. was among the top detractors from performance. Berkeley Lights is a leading digital cell biology company founded in 2011. The company provides a single cell manipulation platform to enable and accelerate rapid development and commercialization of biotherapeutics and other cell-based products. The Berkeley Lights platform provides an advanced environment for rapid functional characterization of single cells at scale, with advanced automation systems that analyze live cells using proprietary consumables and application and workflow software to deliver robust single cell data. Berkeley Lights' workflows enable a deep understanding of each cell's behavior by recording critical data such as relevant phenotypic characteristics and linking to genetic information using real -time continuous images on thousands of cells, cell by cell. The company drastically reduces the amount of time required to get results for each of these application workflows by using customer defined criteria to find the best eel I for each customer's desired product.

We believe the underperformance of Berkeley Lights shares during the first quarter was driven more by heavy insider selling than by a change in fundamentals and we believe the base business remains strong. For example, the company recently announced a new$17 mi11ion multi-year non-exclusive collaboration agreement with a global leader in the contract development and manufacturing organization (COMO) space, which will expand the company's total addressable market and potentially allow the company to develop new workflows that it can commercialize in the future. More broadly, Berkeley Lights has tail winds from strong demand for cell -based products, increasing complexity of these products and a growing number of therapeutic modalities, all of which should drive demand for the company's technology."

/ / / / / / Berkley Lights BLI @ $43.50 / / / / / /

For your consideration: a stk down a whole lot... This is Pt 1 of a continuing series called Bottoms Up! Down & Out stocks with Promise & Potential. ~si
 
Take a look at the chart of BLI it's very interesting. This will either go to $50 or $75.

I see an attempt right now to get back on it's feet the 1 month is instructive with MAC D turning up and we are right at a trend line which we retreated from. <-- First red bar in a while...

I think I'm going to buy this on Monday or Tues.
 
Great stuff! Around 12:00 we talk about patents but we use a very funny accent.

Then it comes out much later- Cathy Arkk has bought a ton!!<-- Wooooooooo Hoooooo! And it's down a ton Are we smarter than Cathy! / / / /

This is why investing is so fun. The research. I can start with a blank slate and just by surfing find a name and by researching find a story, an angle and a reason! booo ya!!!!
 
stonedinvestor said:
BOTTOMS UP -!
More...
200w.gif
 
You must log in or register to reply here.
Back
Top